Evidence map›Paper›PMID 26374598›Full record

ArticleFuture oncology (London, England)2015

Harnessing novel modalities: field carcinogenesis detection for personalizing prostate cancer management.

Navneet Momi, Vadim Backman, Charles B Brendler, Hemant K Roy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Navneet MomiDepartment of Internal Medicine, Boston University Medical Center, Boston, MA 02118, USA.
Vadim BackmanBiomedical Engineering Department, Northwestern University, Evanston, IL 60208, USA.
Charles B BrendlerUrology Department, NorthShore University HealthSystems, Evanston, IL 60201, USA.
Hemant K RoyDepartment of Internal Medicine, Boston University Medical Center, Boston, MA 02118, USA.

Funding

Spectral Markers for Early Detection of Colon NeoplasiaU01CA111257 · NCI · NORTHSHORE UNIV HEALTHSYSTEM RES INST · PI BACKMAN, VADIM, ROY, HEMANT K. · 2004 to 2015
$6.0M
Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer ScreeningR01CA165309 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, ROY, HEMANT K. · 2012 to 2016
$2.8M
NanoCytology to mitigate overdiagnosis of prostate cancerR44CA192701 · NCI · NANOCYTOMICS, LLC · PI SUBRAMANIAN, HARIHARAN · 2015 to 2017
$1.7M
NCI NIH HHS 1R44CA192701NCI NIH HHS R01 CA165309NCI NIH HHS R01CA165309NCI NIH HHS R44 CA192701NCI NIH HHS U01 CA111257NCI NIH HHS U01CA111257
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CarcinogenesisBiomarkers, TumorEarly Detection of CancerHumansMaleMicroRNAsPrecision MedicineProstatic NeoplasmsBiomarkers, TumorMicroRNAsbiomarkermiRNAsnanocytologyoverdiagnosisprostate cancerPWS

Identifiers

PMID26374598
PMCPMC4868392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.